Literature DB >> 9782535

Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group.

T Witte1, K Hartung, T Matthias, C Sachse, M Fricke, H Deicher, J R Kalden, H J Lakomek, H H Peter, R E Schmidt.   

Abstract

Previously it has been suggested that the presence of antibodies against dsDNA of the IgA class may define a subset of systemic lupus erythematosus (SLE) patients suffering from nephritis and arthritis. Therefore, these autoantibodies were measured in sera of 352 patients with SLE, 81 blood donors, and 189 patients with rheumatoid arthritis using a new ELISA based on human recombinant dsDNA as antigen. IgA anti-dsDNA antibodies were found in 19.9% of the sera from patients with SLE, but in none of the sera from 81 normal controls and 189 patients with rheumatoid arthritis. The association of these autoantibodies with 31 clinical and 36 laboratory parameters was calculated. IgA anti-dsDNA antibodies were found to be associated with parameters of disease activity such as elevated erythrocyte sedimentation rate and consumption of complement component C3, and the clinical parameters vasculitis, with necrosis and erythema, but not with nephritis and arthritis. Therefore, IgA anti-dsDNA antibodies define a subset of SLE patients, and monitoring of IgA anti-dsDNA antibodies may be helpful as a prognostic parameter in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9782535     DOI: 10.1007/s002960050059

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  7 in total

1.  C4 Deficiency is a predisposing factor for Streptococcus pneumoniae-induced autoantibody production.

Authors:  Rama D Yammani; Marcela A Leyva; Ryan N Jennings; Karen M Haas
Journal:  J Immunol       Date:  2014-10-22       Impact factor: 5.422

2.  Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.

Authors:  G S Alarcón; J Calvo-Alén; G McGwin; A G Uribe; S M A Toloza; J M Roseman; M Fernández; B J Fessler; L M Vilá; C Ahn; F K Tan; J D Reveille
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

3.  Anti-dsDNA antibodies in Brazilian patients of mainly African descent with systemic lupus erythematosus: lack of association with lupus nephritis.

Authors:  A M Atta; M M Pereira; M Santiago; M L B Sousa-Atta
Journal:  Clin Rheumatol       Date:  2009-03-13       Impact factor: 2.980

4.  Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.

Authors:  Till Fassbinder; Ute Saunders; Eva Mickholz; Elisabeth Jung; Heidemarie Becker; Bernhard Schlüter; Annett Marita Jacobi
Journal:  Arthritis Res Ther       Date:  2015-04-03       Impact factor: 5.156

5.  Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease.

Authors:  Danilo Villalta; Nicola Bizzaro; Nicola Bassi; Margherita Zen; Mariele Gatto; Anna Ghirardello; Luca Iaccarino; Leonardo Punzi; Andrea Doria
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

6.  Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis.

Authors:  Barbara Dema; Christophe Pellefigues; Sarfaraz Hasni; Nathalie Gault; Chao Jiang; Tiffany K Ricks; Michael M Bonelli; Jörg Scheffel; Karim Sacré; Mathieu Jablonski; Delphine Gobert; Thomas Papo; Eric Daugas; Gabor Illei; Nicolas Charles; Juan Rivera
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

7.  Anti-Double-Stranded DNA Isotypes and Anti-C1q Antibody Improve the Diagnostic Specificity of Systemic Lupus Erythematosus.

Authors:  Yu Jia; Lingling Zhao; Chunyan Wang; Jin Shang; Yi Miao; Yangyang Dong; Zhanzheng Zhao
Journal:  Dis Markers       Date:  2018-09-27       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.